Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis.

Peiró-Aventín, BelénCabrera-Romero, EvaMora-Ayestarán, NereaDomínguez, FernandoGonzález-López, EstherGarcia-Pavia, Pablo2024-07-112024-07-112024-05Rev Esp Cardiol. 2024 May;77(5):426-428.http://hdl.handle.net/20.500.12105/20518engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Amyloid Neuropathies, FamilialDiflunisalCardiomyopathiesHumansMaleFemaleAgedTreatment OutcomeMiddle AgedSafety and efficacy of diflunisal in transthyretin cardiac amyloidosis.Attribution-NonCommercial-NoDerivatives 4.0 Internacional3832570077542610.1016/j.rec.2023.10.0161885-5857Revista espanola de cardiologia (English ed.)open access